Stock Performance And Forecast For NovoCure Ltd

In the last trading session, 1.15 million NovoCure Ltd (NASDAQ:NVCR) shares changed hands as the company’s beta touched 0.40. With the company’s per share price at $16.10 changed hands at $0.79 or 5.16% during last session, the market valuation stood at $1.72B. NVCR’s last price was a discount, traded about -452.98% off its 52-week high of $89.03. The share price had its 52-week low at $10.87, which suggests the last value was 32.48% up since then. When we look at NovoCure Ltd’s average trading volume, we note the 10-day average is 1.09 million shares, with the 3-month average coming to 0.83.

NovoCure Ltd (NASDAQ:NVCR) trade information

Instantly NVCR was in green as seen at the end of in last trading. With action 17.26%, the performance over the past five days has been green. The jump to weekly highs of 16.14 added 5.16% to the stock’s daily price. The company’s shares are showing year-to-date upside of 7.84%, with the 5-day performance at 17.26% in the green. However, in the 30-day time frame, NovoCure Ltd (NASDAQ:NVCR) is 18.91% up. Looking at the short shares, we see there were 5.77 million shares sold at short interest cover period of 3.86 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

NovoCure Ltd (NVCR) estimates and forecasts

Data shows that the NovoCure Ltd share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -48.46% over the past 6 months, a -131.82% in annual growth rate that is considerably lower than the industry average of 4.70%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.89%. The 2024 estimates are for NovoCure Ltd earnings to decrease by -129.97%.

NVCR Dividends

NovoCure Ltd is expected to release its next quarterly earnings report on February 22.

NovoCure Ltd (NASDAQ:NVCR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.26% of NovoCure Ltd shares while 84.51% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 85.59%. There are 84.51% institutions holding the NovoCure Ltd stock share, with FMR, LLC the top institutional holder. As of Jun 29, 2023, the company held 14.94% of the shares, roughly 15.93 million NVCR shares worth $661.1 million.

Capital World Investors holds the second largest percentage of outstanding shares, with 10.68% or 11.39 million shares worth $472.71 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Growth Fund Of America Inc and Fidelity Growth Company Fund. With 7.53 million shares estimated at $312.3 million under it, the former controlled 7.06% of total outstanding shares. On the other hand, Fidelity Growth Company Fund held about 4.38% of the shares, roughly 4.67 million shares worth around $103.13 million.

On Key

Related Posts